首页> Annals of oncology : official journal of the European Society for Medical Oncology> Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.

导出 OA

翻译打印收藏纠错

第一作者： E,Calvo

第一单位： START Madrid - Oncology, HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid.

作者： E,Calvo ^[1] ; V,Moreno ^[2] ; M,Flynn ^[3] ; E,Holgado ^[1] ; M E,Olmedo ^[4] ; M P,Lopez Criado ^[5] ; C,Kahatt ^[6] ; J A,Lopez-Vilariño ^[6] ; M,Siguero ^[6] ; C,Fernandez-Teruel ^[6] ; M,Cullell-Young ^[6] ; A,Soto Matos-Pita ^[6] ; M,Forster ^[7]

作者单位： START Madrid - Oncology, HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid. ^[1] START Madrid - Oncology, FJD (Hospital Fundación Jiménez Díaz), Madrid, Spain. ^[2] Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK. ^[3] Department of Oncology, Hospital Ramon y Cajal, Madrid. ^[4] Department of Oncology, M.D. Anderson Cancer Center, Madrid. ^[5] Clinical R&D, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain. ^[6] Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK;. Electronic address: m.forster@ucl.ac.uk. ^[7]

关键词 PM01183 lurbinectedin phase I study small-cell lung cancer